Dah Sing Banking (2356.HK) traded down -0.85 % during a 24 hours period ending at 03:24 PM Central Europe on Monday 26th. One Dah Sing Banking stock can currently be bought for about HKD 12.84 on popular exchanges. Current supply of Dah Sing Banking stocks is 1.4 bn. Dah Sing Banking has a current market capitalization of HKD 18.1 bn and approximately HKD 26.6 mn worth of Dah Sing Banking was traded on exchanges in the last 24 hours. Since last month end, Dah Sing Banking has traded -11.11 % down. Simple moving average of last 200 days is at HKD 12.95. The highest price of past 52 weeks was recorded at HKD 15.45 on 07/29/2026. 52 weeks low was at HKD 10.4 on 01/21/2026.

Here is how related stocks have performed in the past 24 hours:

  • Gcl (3800.HK) traded down -4 % and now trades at HKD 0.61. Gcl has a market capitalisation of HKD 19.3 bn.

  • First Pacific (0142.HK) traded up 1.08 % and now trades at HKD 4.78. Current market capitalisation for First Pacific is HKD 19.9 bn. First Pacific has a current price to earnings ratio of 4.46.

  • Ts Lines (2510.HK) traded down -1.28 % and now trades at HKD 12.69. Ts Lines has a market capitalisation of HKD 20.5 bn.

  • Oshidori Holdi (0622.HK) traded up 3.33 % and now trades at HKD 3.14. Current market capitalisation for Oshidori Holdi is HKD 21.5 bn. Current price/earnings ratio for Oshidori Holdi is 54.14.

  • Hutchmed China (0013.HK) traded up 0.98 % and now trades at HKD 22.56. Hutchmed China has a market capitalisation of HKD 19.6 bn. Hutchmed China has a current price to earnings ratio of 142.72. AstraZeneca’s experimental antibody drug conjugate, sonesitatug vedotin, has demonstrated a substantial survival benefit in a late‑stage gastric‑cancer study. In patients whose disease progressed after at least one line of therapy, the agent extended median overall survival by approximately five months compared with standard chemotherapy, while maintaining a manageable safety profile. The benefit was most pronounced in patients receiving the drug after two prior therapies. The data, presented at the European Society for Medical Oncology Congress, support the potential of sonesitatug vedotin to replace conventional chemotherapy in this setting and suggest a significant commercial opportunity for the company.

About Dah Sing Banking

The Dah Sing Banking Group Ltd is a financial institution operating in the commercial banking sector with its main operations based in Hong Kong. The Group provides personal banking, commercial banking, and treasury services through its subsidiaries. Their webseite is www.dahsing.com and they are listed on the Hong Kong Stock Exchange. Their Initial Public Offering (IPO) took place on June 30th, 2004.